You are here

  • Home
  • Archive
  • Volume 80, Issue 4
  • Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Article Text

Article menu
Download PDFPDF
Correspondence
Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
  1. Lionel Carbillon1,2,
  2. Amélie Benbara1,
  3. Jeremy Boujenah1
  1. 1 Obstetrics and Gynecology, Assistance Publique - Hopitaux de Paris, Bondy, France
  2. 2 Obstetrics and Gynecology, Sorbonne Paris Nord University, Bondy, France
  1. Correspondence to Professor Lionel Carbillon, Obstetrics & Gynecology, Assistance Publique Hopitaux de Paris, Bondy, France; lionel.carbillon{at}aphp.fr

https://doi.org/10.1136/annrheumdis-2020-217847

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    As obstetricians with a maternal–foetal medicine practice taking care of pregnant women treated with hydroxychloroquine (HCQ) in the prevention of systemic lupus erythematosus (SLE) flare, we read with interest the recent report of clinical data collected through the COVID-19 Global Rheumatology Alliance registry.1 Indeed, in the current epidemic, a number of cases of severe acute respiratory syndrome have occurred worldwide in pregnant women and have jeopardised both mother and fetus and have sometimes led to extreme prematurity, confirming reports from previous coronavirus outbreaks.2 Hence, any safe treatment with a potential for prevention of severe forms of COVID-19 would be of great interest. As HCQ used in the prevention of SLE flare has a good safety profile during pregnancy, and its …

    View Full Text

    Footnotes

    • Contributors LC, AB and JB contributed to the critical analysis of the articles. LC wrote the main document.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles